Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) EBT (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of EBT data on record, last reported at -$25.5 million in Q4 2021.

  • For Q4 2021, EBT fell 124.27% year-over-year to -$25.5 million; the TTM value through Dec 2021 reached -$75.1 million, up 8.5%, while the annual FY2025 figure was -$321.7 million, 24.78% down from the prior year.
  • EBT reached -$25.5 million in Q4 2021 per COGT's latest filing, down from -$19.7 million in the prior quarter.
  • Across five years, EBT topped out at $2.3 million in Q4 2019 and bottomed at -$57.2 million in Q3 2020.
  • Average EBT over 4 years is -$14.0 million, with a median of -$11.0 million recorded in 2019.
  • Peak YoY movement for EBT: skyrocketed 126.77% in 2019, then plummeted 594.78% in 2020.
  • A 4-year view of EBT shows it stood at -$8.6 million in 2018, then surged by 126.77% to $2.3 million in 2019, then tumbled by 594.78% to -$11.4 million in 2020, then crashed by 124.27% to -$25.5 million in 2021.
  • Per Business Quant database, its latest 3 readings for EBT were -$25.5 million in Q4 2021, -$19.7 million in Q3 2021, and -$17.2 million in Q2 2021.